BIO Professional Development
Through a curated network of education alliance partners, BIO offers industry professionals executive training and development resources for accelerating career growth
06/02/2023 - 06/04/2023 | 8:30 AM - 5:45 PM EDT
Advanced Business Development
Advanced Business Development (ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. This course is ideal for professionals ranging from those with limited experience (2–3 years) looking to advance their skills; and highly experienced dealmakers or executives looking to hone their skills and network with other dealmakers.
Advanced Business Development incorporates lecture from experienced dealmakers, review of example models, dissection of actual deals, interaction with other participants, and live Q&A. Also, the course includes a mock negotiation scenario when each participant is a member of a deal team assigned to negotiate a transaction involving a drug in development with another team using an actual valuation and deal structuring model.
This course will be held in person, June 2-4, 2023, in Boston, Mass.
Interested in only registering for an in-person course in Boston? For course-only registration instructions, email: email@example.com
Instructors (click photos to view bios)
- Business development practices
- Trends in BD transactions
- Valuation, analytics, and models
- Deal structuring
- Intellectual property
- Legal terms, term sheets, and agreements
- Due diligence
- Live, interactive case study work
Download Course Syllabus
- Attend the entire in-person course
- Complete course evaluation within two weeks of the course end date
Learn the core elements of revenue forecasting.
Experienced dealmakers will prove a deep dive on early capitalization from investors (not grants).
Learn about the science driving today’s hottest biopharma innovations including CRISPR, CAR-T, gene therapy, and much more...
Gain a systematic approach to producing a valuation that can be used in investment rounds, mergers/acquisitions, licensing deals or strategic development decisions in the pharma-biotech world...